Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.
Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.
复制标题
DOI：
10.1016/j.vaccine.2015.01.028
复制
发表时间：
2015-02-18
期刊：
影响因子：
5.5
通讯作者：
Hosie MJ
中科院分区：
文献类型：
--
作者：
Bęczkowski PM;Harris M;Techakriengkrai N;Beatty JA;Willett BJ;Hosie MJ
FIV疫苗接种猫筛选中和抗体Homeland中和50%测试猫无异源中和在人类和兽医学中，仅针对两种逆转录病毒感染的疫苗已成功上市，即针对猫白血病病毒（FeLV）和猫免疫缺陷病毒（FIV）的疫苗。FeLV疫苗是一个全球性的成功案例，在接种率高的国家降低了病毒流行率。相比之下，最近的FIV疫苗于2002年推出，在该领域提供的保护程度仍有待确定。然而，鉴于FIV和HIV之间的相似性，FIV疫苗有效性的实地研究可能会为未来HIV疫苗接种方法的发展提供建议和信息。在此，我们通过检测从客户拥有的接种疫苗的澳大利亚猫中采集的血样，评估了FIV疫苗接种诱导的针对一组FIV分离株的中和抗体应答。我们检测了从一只接种疫苗的猫中分离的24个env的分子和表型特性，我们推测这些猫可能在自然暴露于FIV后感染。接种FIV疫苗的猫没有显示出广泛的中和抗体，这表明保护可能不会延伸到在澳大利亚流行的一些FIV强毒重组株。
FIV vaccinated cats screened for neutralising antibodies Homologous neutralisation in 50% of cats tested No heterologous neutralisation Across human and veterinary medicine, vaccines against only two retroviral infections have been brought to market successfully, the vaccines against feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV). FeLV vaccines have been a global success story, reducing virus prevalence in countries where uptake is high. In contrast, the more recent FIV vaccine was introduced in 2002 and the degree of protection afforded in the field remains to be established. However, given the similarities between FIV and HIV, field studies of FIV vaccine efficacy are likely to advise and inform the development of future approaches to HIV vaccination. Here we assessed the neutralising antibody response induced by FIV vaccination against a panel of FIV isolates, by testing blood samples collected from client-owned vaccinated Australian cats. We examined the molecular and phenotypic properties of 24 envs isolated from one vaccinated cat that we speculated might have become infected following natural exposure to FIV. Cats vaccinated against FIV did not display broadly neutralising antibodies, suggesting that protection may not extend to some virulent recombinant strains of FIV circulating in Australia.
登录
查看更多内容
影响因子：
3.3
作者：
Bęczkowski PM;Hughes J;Biek R;Litster A;Willett BJ;Hosie MJ
通讯作者：
Hosie MJ
影响因子：
5.4
作者：
Casimiro, DR;Tang, AM;Shiver, JW
通讯作者：
Shiver, JW
影响因子：
5.5
作者：
Elyar, JS;Tellier, MC;Yamamoto, JK
通讯作者：
Yamamoto, JK
影响因子：
168.9
作者：
Buchbinder, Susan P.;Mehrotra, Devon V.;Duerr, Ann;Fitzgerald, Daniel W.;Mogg, Robin;Li, David;Gilbert, Peter B.;Lama, Javier R.;Marmor, Michael;del Rio, Carlos;McElrath, M. Juliana;Casimiro, Danilo R.;Gottesdiener, Keith M.;Chodakewitz, Jeffrey A.;Corey, Lawrence;Robertson, Michael N.
通讯作者：
Robertson, Michael N.
影响因子：
3.8
作者：
GRAHAM, FL;SMILEY, J;NAIRN, R
通讯作者：
NAIRN, R